| Name | Title | Contact Details |
|---|---|---|
Kathleen Zarsky |
Chief Information Security Officer | Profile |
David D |
Vice President, Information Technology and Chief Information Security Officer | Profile |
David Demsey |
Vice President, Information Technology and Chief Information Security Officer | Profile |
Nolan Bennett |
Chief Information Officer | Profile |
Mayne Pharma is a fast growing company, focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, with operations in Australia and the US. The Company has grown substantially and reflects the hard work and de...
Directories team of high-level marketing can-do-it-alls seamlessly join your team, dig in and get things done.
We have a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products. As a leading global player in specialty, branded and generic pharmaceuticals, we have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to increase the number of lives benefiting from our products that reach more than 150 countries. In line with the our commercial, production and territorial strategies, we have identified Thrombosis, Anaesthetics, High Potency & Cytotoxics as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.